Cargando…

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Wahab, Reham, Shehata, Samir, Hassan, Manal M, Habra, Mouhammed A, Eskandari, Ghazaleh, Tinkey, Peggy T, Mitchell, Jennifer, Lee, Ju-Seog, Amin, Hesham M, Kaseb, Ahmed O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918293/
https://www.ncbi.nlm.nih.gov/pubmed/27508202
http://dx.doi.org/10.2147/JHC.S81309
_version_ 1782439097735839744
author Abdel-Wahab, Reham
Shehata, Samir
Hassan, Manal M
Habra, Mouhammed A
Eskandari, Ghazaleh
Tinkey, Peggy T
Mitchell, Jennifer
Lee, Ju-Seog
Amin, Hesham M
Kaseb, Ahmed O
author_facet Abdel-Wahab, Reham
Shehata, Samir
Hassan, Manal M
Habra, Mouhammed A
Eskandari, Ghazaleh
Tinkey, Peggy T
Mitchell, Jennifer
Lee, Ju-Seog
Amin, Hesham M
Kaseb, Ahmed O
author_sort Abdel-Wahab, Reham
collection PubMed
description Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials.
format Online
Article
Text
id pubmed-4918293
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49182932016-08-09 Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma Abdel-Wahab, Reham Shehata, Samir Hassan, Manal M Habra, Mouhammed A Eskandari, Ghazaleh Tinkey, Peggy T Mitchell, Jennifer Lee, Ju-Seog Amin, Hesham M Kaseb, Ahmed O J Hepatocell Carcinoma Review Chronic liver diseases (CLDs) encompass a wide range of illnesses, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and viral hepatitis. Deterioration of liver capacity, with subsequent progression into cirrhosis and hepatocellular carcinoma (HCC), ultimately leads to a further decrease in the hepatic reserve. The Child–Turcotte–Pugh scoring system is the standard tool for assessing underlying liver reserve capacity in routine practice and in clinical trials of CLD and HCC. In this review, we highlight the clinical significance of insulin-like growth factor-I (IGF-I) and the growth hormone (GH) signaling pathway in HCC. IGF-I could be a marker for liver reserve capacity in CLDs and HCC in clinical practice. This approach could improve the risk assessment and stratifications of patients on the basis of their underlying liver reserve, either before active treatment in routine practice or before they are enrolled in clinical trials. Dove Medical Press 2015-09-18 /pmc/articles/PMC4918293/ /pubmed/27508202 http://dx.doi.org/10.2147/JHC.S81309 Text en © 2015 Abdel-Wahab et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Abdel-Wahab, Reham
Shehata, Samir
Hassan, Manal M
Habra, Mouhammed A
Eskandari, Ghazaleh
Tinkey, Peggy T
Mitchell, Jennifer
Lee, Ju-Seog
Amin, Hesham M
Kaseb, Ahmed O
Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title_full Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title_fullStr Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title_full_unstemmed Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title_short Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
title_sort type i insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918293/
https://www.ncbi.nlm.nih.gov/pubmed/27508202
http://dx.doi.org/10.2147/JHC.S81309
work_keys_str_mv AT abdelwahabreham typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT shehatasamir typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT hassanmanalm typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT habramouhammeda typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT eskandarighazaleh typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT tinkeypeggyt typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT mitchelljennifer typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT leejuseog typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT aminheshamm typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma
AT kasebahmedo typeiinsulinlikegrowthfactorasaliverreserveassessmenttoolinhepatocellularcarcinoma